Nektar: "Strong Buy" On REZPEG POC Established In AD/AA And Late-Stage Development (NKTR)
Summary
Nektar Therapeutics stock is upgraded from 'Buy' to 'Strong Buy' following robust phase 2b data for REZPEG in atopic dermatitis [AD] and alopecia areata [AA]. R...
Description
Nektar Therapeutics stock is upgraded from 'Buy' to 'Strong Buy' following robust phase 2b data for REZPEG in atopic dermatitis [AD] and alopecia areata [AA]. R...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source